George Yancopoulos, President and Chief Scientific at REGENERON PHARMACEUTICALS, INC. (REGN), sold 6,165 shares at $803.30 ($5.0M) on 2023-03-23, disclosed to the SEC on 2023-03-27.
Scheduled sale ($5.0M) by President and Chief Scientific under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $800.59 | 254 | $203K | 4.1% |
| 2 | $800.59 | 254 | $203K | 4.1% |
| 3 | $801.16 | 122 | $98K | 2.0% |
| 4 | $801.16 | 122 | $98K | 2.0% |
| 5 | $802.54 | 1,237 | $993K | 20.0% |
| 6 | $802.54 | 1,237 |
| $993K |
| 20.0% |
| 7 | $803.30 | 642 | $516K | 10.4% |
| 8 | $803.30 | 642 | $516K | 10.4% |
| 9 | $804.38 | 254 | $204K | 4.1% |
| 10 | $804.38 | 254 | $204K | 4.1% |
| 11 | $805.55 | 47 | $38K | 0.8% |
| 12 | $806.47 | 700 | $565K | 11.4% |
| 13 | $810.30 | 400 | $324K | 6.5% |
| Total | $803.61 avg | 6,165 | $5.0M | 100% |
| Filing → |
| REGN | SELL | 2024-01-04 | $15.2M | — | Filing → |
| REGN | SELL | 2023-02-08 | $21.1M | — | Filing → |
| REGN | SELL | 2021-08-17 | $62.0M | — | Filing → |